Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 5/20 | 0.38 |
| ▸ | SMC2 | O95347 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.38 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.38 |
| ▸ | SMC1A | Q14683 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.38 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2021275 | 0.91 | MAP2K1 (0.39) | MAP2K1SMC2EGFRCSNK2A2MAP2K2 | |
| SCHEMBL3862511 | 0.86 | AAK1 (0.35) | MAP2K1SMC2EGFRCSNK2A2MAP2K2 | |
| SCHEMBL19119162 | 0.86 | MAP2K1 (0.37) | MAP2K1SMC2EGFRCSNK2A2MAP2K2 | |
| SCHEMBL1040290 | 0.85 | MAP2K1 (0.40) | MAP2K1SMC2EGFRCSNK2A2MAP2K2 | |
| SCHEMBL3861298 | 0.84 | MAP2K1 (0.39) | MAP2K1SMC2EGFRCSNK2A2MAP2K2 | |
| SCHEMBL19141367 | 0.83 | TP53 (0.33) | MAP2K1SMC2EGFRCSNK2A2MAP2K2 | |
| SCHEMBL3861938 | 0.82 | MAP2K1 (0.39) | MAP2K1SMC2EGFRCSNK2A2MAP2K2 | |
| SCHEMBL3861235 | 0.82 | MAP2K1 (0.37) | MAP2K1SMC2EGFRCSNK2A2MAP2K2 | |
| SCHEMBL3860279 | 0.82 | MAP2K1 (0.55) | MAP2K1SMC2EGFRCSNK2A2MAP2K2 | |
| SCHEMBL1039631 | 0.81 | MAP2K1 (0.44) | MAP2K1SMC2EGFRCSNK2A2MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2275102-B1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA INC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-8513293-B2 | Methods of treating a hyperproliferative disorder or inhibiting cell growth in a mammal | ARRAY BIOPHARMA INC. (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2130536-B1 | N3 alkylated benzimidazole derivatives as mek inhibitors | ARRAY BIOPHARMA INC (US) | 2013-05-08 | — | — | EP | disclosed |
| EP-2130537-B1 | N3 alkylated benzimidazole derivatives as mek inhibitors | ARRAY BIOPHARMA INC (US) | 2012-11-14 | — | — | EP | disclosed |
| US-20120277277-A1 | Methods of Treating a Hyperproliferative Disorder or Inhibiting Cell Growth in a Mammal | ARRAY BIOPHARMA INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-8003805-B2 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20100261718-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261717-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-10-14 | — | — | US | disclosed |
| EP-1663210-A4 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC (US) | 2009-04-22 | — | — | EP | disclosed |
| US-7425637-B2 | mitogen-activated protein/extracellular signal-regulated (MAP/ERK)Kinase pathways; 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethoxy)-amide; hyperproliferative diseases; anticarcinogenic and antiinflammatory agent | ARRAY BIOPHARMA INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-20080171778-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-07-17 | — | — | US | disclosed |
| EP-1663210-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | Array Biopharma, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1482932-A4 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC (US) | 2006-04-05 | — | — | EP | disclosed |
| US-20050143438-A1 | N3 alkylated benzimidazole derivatives as MEk inhibitors | ALEXION PHARMA INTERNATIONAL OPERATIONS LIMITED (IE) | 2005-06-30 | — | — | US | disclosed |
| WO-2005023251-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| EP-1482932-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | Array Biopharma, Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20030232869-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ASTRAZENECA AB (SE) | 2003-12-18 | — | — | US | disclosed |
| WO-2003077914-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA, INC (US) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261718-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | BRAF, CDK9, NRAS | MAP2K1 198/4885SMC2 3317/4885EGFR 235/4885 |
| US-20080171778-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | BRAF, CCNI, NRAS | MAP2K1 164/4885SMC2 3447/4885EGFR 206/4885 |
| US-20120277277-A1 | Methods of Treating a Hyperproliferative Disorder or Inhibiting Cell Growth in a Mammal | PCNA, MKI67, HRAS | MAP2K1 1776/4885SMC2 710/4885EGFR 273/4885 |
| US-20030232869-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | CCNI, BRAF, CDK2 | MAP2K1 106/4885SMC2 2986/4885EGFR 251/4885 |
| US-20050143438-A1 | N3 alkylated benzimidazole derivatives as MEk inhibitors | BRAF, CCNI, NRAS | MAP2K1 164/4885SMC2 3447/4885EGFR 206/4885 |
| US-20100261717-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | BRAF, CCNI, NRAS | MAP2K1 164/4885SMC2 3447/4885EGFR 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.